The Medical Advisor

Weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped obesity treatment. By 2026, millions of people are using GLP-1 receptor agonists or dual GLP-1/GIP drugs to lose weight, improve metabolic health, and reduce cardiometabolic risk. But there’s a hidden issue clinicians are increasingly discussing: Up to 30–40% of the weight lost on GLP-1 therapy can come from lean muscle mass. If that muscle loss isn’t addressed, patients may reach their goal weight but end up with slower metabolism, reduced strength, and higher long-term weight regain risk. This is sometimes called “GLP-1 muscle drain.” The solution isn’t stopping the medication. Instead, experts are increasingly recommending a Protein-Sparing Protocol —a structured approach designed to preserve muscle while maximizing fat loss. Below is the practical, evidence-informed roadmap. 1. The Problem: The “Muscle Drain” Phenomenon GLP-1 medications work primarily by: Slowing gastric emptying Increasing satie...

Abstract Background: Stage 4 cancer — defined by metastatic spread beyond the original tumor site — has a poor prognosis with conventional treatment alone. There is growing interest in repurposed antiparasitic drugs such as ivermectin , fenbendazole , and mebendazole for potential antineoplastic effects. Preclinical research suggests mechanisms including disruption of oncogenic signaling pathways and inhibition of cancer cell proliferation and survival, but controlled clinical evidence in humans remains limited. Objective: To summarize and characterize a large compilation of anecdotal clinical case reports describing the use of ivermectin, fenbendazole, and mebendazole in individuals with Stage 4 cancers (various tumor types) and to highlight reported outcomes and therapeutic contexts. Methods: Over 320 individual case reports were aggregated from public sources — predominantly social media posts, practitioner-shared testimonials, and independently published patient narratives....